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Using ATPcc% as radioligand, we have detected the presence of specific purinoceptors on human liver plasma mem- 
branes. They are characterized by a & value of 0.19 PM and a B,,,,, of 24 pmol/mg membrane protein. These purinocep- 
tors belong to the PzY subclass as demonstrated by the high degree of similarity with rat liver purinoceptors, previously 
shown to be Pry [(1986) Biochem. J. 240, 367-3711 and known to be involved in the control of liver glycogenolysis. 
Purinoceptor; Glycogenolysis; (Human liver) 
1. INTRODUCTION 
As reviewed by Burnstock and Kennedy [l] and 
Gordon [2], extracellular ATP and ADP at 
micromolar concentrations can influence many 
biological processes. On the basis of extensive 
pharmacological studies, two subclasses of 
purinoceptors have been described: Pi-receptors 
are more sensitive to adenosine and AMP, 
positively linked to adenylate cyclase and blocked 
by methylxanthines; Pz-receptors are more specific 
for ATP and ADP, not antagonized by methylxan- 
thines and not linked to adenylate cyclase. Burn- 
stock and Kennedy [l] have proposed 
distinguishing Pz-purinoceptors via classification 
into two subtypes, designated POX and PZY. The 
Pzx-subtype shows a specific rank order of potency 
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of PPWI~IPA = p[CH2]ppA > ATP = 
2-methylthio-ATP and is selectively desensitized 
by pp[CH2]pA. The P2v-subtype displays a dif- 
ferent rank order of potency (Zmethylthio-ATP % 
ATP > PPKH~IPA = p[CH2]ppA) and is only 
weakly, if at all, desensitized by pp[CH2]pA. 
Rat liver glycogenolysis is clearly regulated by 
submicromolar concentrations of ATP and ADP 
[3-71. These studies have shown that the 
purinoceptors involved belong to the P2-class and 
initiate CAMP-independent, calcium-dependent 
glycogenolysis. Using ATPa3?S as radioligand, we 
[8] demonstrated the presence of specific high- 
affinity Pzv-purinoceptors in rat liver. The present 
study shows that plasma membranes from human 
liver also possess Pzv-purinoceptors very similar to 
those of rat liver and suggests therefore that in 
man, liver metabolism is possibly under purinergic 
control. 
2. MATERIALS AND METHODS 
2.1. Materials 
ATP&, ATPo3sS and [‘H]dihydroalprenolol were purchas- 
ed from Amersham International (England); reactive blue (a 
Psy-antagonist according to [9]) from Janssen (Beerse); and 
diadenosine triphosphate (ApsA) and tetraphosphate (Ap4A) 
from Sigma (St. Louis, MO). These dinucleotides have been 
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shown to increase glycogen phosphorylase in isolated rat 
hepatocytes [lo] and we have confirmed this observation. We 
also checked that reactive blue antagonizes the glycogenolytic 
activity of ATP as tested in rat hepatocytes. The sources of 
other chemicals have been described in [3,8]. 
The computer program ‘Enzfitter’ was from Elsevier Biosoft 
(Cambridge, England). 
2.2. Methods 
Rat liver plasma membranes were isolated as in [ll] with 
minor modifications [8]. Tumor-free non-cirrhotic human liver 
samples were obtained from patients undergoing hemihepatec- 
tomy for benign or malignant umors. Approval was obtained 
from the ethical commission of the Faculty of Medicine. Tissue 
samples were frozen in liquid nitrogen and kept at - 80°C. For 
preparation of liver plasma membranes, liver was first 
powdered in a mortar under liquid Nz. The subsequent pro- 
cedure was according to [12]. 
We verified that adenylate cyclase of plasma membrane 
preparations was stimulated by glucagon (3-4-fold) and NaF 
(6-fold). We also checked that for human liver plasma mem- 
branes the binding of [‘Hldihydroalprenolol (& = 0.9 nM and 
B max = 76 fmol/mg membrane protein) was similar to that 
described in [12]. 
ATPa3’S binding to purified plasma membranes and deter- 
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Fig. 1. Association-dissociation pattern for the binding of 
ATPa3jS to human liver plasma membranes. Plasma 
membranes (0.6 mg protein/ml) were incubated with 0.12 ,uM 
AT&%; 1 min later excess ATP (1 mM) was added. Total 
[(0) association and (0) dissociation] and non-specific (A) 
binding are plotted vs time. Values are means + SE (where scale 
permits) from 3 independent experiments. 
mination of the dissociation constants of the ATP analogues by 
competition experiments were performed as in [8]. 
3. RESULTS AND DISCUSSION 
Fig. 1 illustrates the time-dependent association 
and dissociation of ATPa3$ with purified human 
liver plasma membranes. The association is rapid, 
equilibrium being reached in less than 1 min, and 
reversible, since the addition of excess ATP results 
in rapid and fairly complete displacement of the 
radioligand. 
Steady-state binding measurements were per- 
formed after 1 min incubation. The dose- 
dependent binding of ATPa3’S to purified human 
liver membranes is shown in fig.2. The binding 
pattern cannot be described adequately by a simple 
Michaelis-Menten equation as is also illustrated by 
the curvilinear Scatchard plot. Computer analysis 
p- 
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Fig.2. Dose dependence of specific ATPa35S binding to 
purified human liver plasma membranes. Liver plasma 
membranes (0.6 mg protein/ml) were incubated with the 
indicated concentrations of ATPcY”S. Specific binding was 
measured after 1 min; values given as means + SE (where scale 
permits) for 6 independent observations. (Inset) Scatchard plot. 
Computer analysis reveals that the data can be accounted for on 
the basis of the existence of a class of high-affinity binding sites 
and of a non-saturable component. For the high-affinity site, 
Kd ( f SE) and B,,, (+ SE) are 0.19 + 0.09pM and 24 + 
9 pmol/mg protein, respectively. 
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of the data reveals that the binding pattern can be 
considered as being the consequence of two in- 
dependent components. One represents saturable 
binding, characterized by a & of 0.19 PM and a 
maximal capacity of 24 pmol/mg protein. The 
other, observed at higher concentrations of 
ATPa”S, can be considered as non-saturable 
binding. This situation is almost identical to that 
observed previously with rat liver membranes 
where the saturable high-affinity sites are 
characterized by a & value of 0.11 PM and a B,,, 
of 30 pmol/mg membrane protein [8]. 
By using several ATP analogues and freshly 
prepared rat hepatocytes, we have obtained 
evidence that, in rat liver, the high-affinity binding 
sites correspond to the receptors mediating the ac- 
tivation of glycogen phosphorylase [8]. We did not 
have human hepatocytes readily available to com- 
pare the biological effects of ATP analogues with 
their binding affinities. Therefore, for a series of 
analogues, we determined the binding affinities for 
human liver plasma membranes in comparison 
with those for rat liver plasma membranes. Table 
1 lists p& values characterizing the affinities of 10 
different agonists and of one antagonist (reactive 
blue) for human and rat liver plasma membranes. 
Table 1 also contains the p& values that we deter- 
Table 1 
Comparison of the p& values of different analOgUeS for rat 
and human liver plasma membranes 
Analog Plasma membranes 
Rat Human 
Cell? 
(rat) 
(1) ATPyS 6.9 f 0.1 (3) 6.3 + 0.1 (4) 5.8 
(2) ATP 6.6 + 0.2 (4) 6.7 + 0.2 (4) 5.7 
(3) ADP 6.2 + 0.2 (5) 6.5 + 0.2 (5) 6.1 
(4) PINHIPPA 5.2 + 0.6 (2) 4.8 + 0.6 (6) 4.8 
(5) Reactive blue 5.1 + 0.2 (3) 4.9 * 0.1 (4) 
(6) PP]CHZIPA 4.9 k 0.1 (3) 4.3 f 0.3 (6) 3.7 
(7) PKHZIPPA 4.9 k 0.1 (3) 4.5 + 0.3 (5) 4.9 
(8) GTP 4.8 rt 0.3 (5) 4.3 f 0.4 (3) 4.6 
(9) APIA 4.4 + 0.1 (2) 3.6 k 0.1 (2) 
(10) Ap3A 4.5 f 0.3 (4) 3.4 * 0.2 (3) 
(11) NADP 2.5 2 0.5 (4) 2.0 f 0.1 (2) 3.3 
a From [8] 
Dissociation constants for binding were calculated from data 
obtained in competition experiments with ATPa3’S, as in [8], 
using a & value for ATPa3%i of 0.19 PM and are expressed in 
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Fig.3. Correlation between p& values of different analogues 
for human and rat liver plasma membranes. Numbers 
correspond to the analogues listed in table 1 (r = 0.9785, P = 
0.0001). 
mined previously for the binding of some 
analogues to intact rat hepatocytes [8]. The latter 
p& values correlate well (r = 0.933, P = 0.0005) 
with those determined in the present article with 
liver plasma membranes, indicating that the 
plasma membrane receptors correspond to those 
found on intact hepatocytes. The data in table 1, 
as shown also in fig.3, show that the p& values 
determined with human plasma membranes corre- 
spond very closely (r = 0.96, P = 0.001) with those 
for rat liver plasma membranes, strongly sug- 
gesting that human and rat liver possess the same 
class of purinoceptors. 
4. CONCLUSION 
This study clearly demonstrates the presence of 
specific purinoceptors on human liver plasma 
membranes. Binding is rapid, essentially reversible 
and dose-dependent. The fact that human and rat 
liver purinoceptors show very similar charac- 
teristics suggests that in man ATP and ADP might 
also control liver metabolism through interaction 
with Pzv-purinoceptors. 
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